• New Zealand has world class scientific research and discoveries.
  • New Zealand has a high quality pipeline of healthtech investment opportunities.

  • Healthcare investing is complex and commercialisation timeframes are often longer and more capital intensive.

  • Healthcare companies that succeed generally have higher returns and higher certainty of returns.

  • The complexity of healthcare technology and the intellectual property created provides significant barriers to entry.

  • Solving health problems that change lives and benefit society through purposeful impact investing is now seen as an imperative.

  • We are in the middle of a healthcare pandemic where the societal benefits and need for healthcare investment and uptake of new technologies has never been so critical and obvious.

Our experience investing in healthtech companies in New Zealand for more than a decade has identified that New Zealand healthtech companies do not typically fail because of the technology or science. They fail from lack of capital, sector specific expertise or understanding of global market access. CaraMed Capital aims to address these challenges.